Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 3/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL11744555 | 0.70 | CA1 (0.52) | CA2CA1LCKPPARDZDHHC20 | |
| SCHEMBL43306 | 0.68 | CA2 (0.55) | CA2CA1LCKPPARDZDHHC20 | |
| SCHEMBL117777 | 0.68 | CA2 (0.55) | CA2CA1LCKPPARDZDHHC20 | |
| SCHEMBL414426 | 0.68 | CA2 (0.55) | CA2CA1LCKPPARDZDHHC20 | |
| SCHEMBL17763250 | 0.68 | CA2 (0.55) | CA2CA1LCKPPARDZDHHC20 | |
| SCHEMBL17763261 | 0.68 | CA2 (0.55) | CA2CA1LCKPPARDZDHHC20 | |
| SCHEMBL17763256 | 0.68 | CA2 (0.55) | CA2CA1LCKPPARDZDHHC20 | |
| SCHEMBL120131 | 0.68 | CA2 (0.55) | CA2CA1LCKPPARDZDHHC20 | |
| SCHEMBL118864 | 0.68 | CA2 (0.55) | CA2CA1LCKPPARDZDHHC20 | |
| SCHEMBL7259121 | 0.68 | CA2 (0.55) | CA2CA1LCKPPARDZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8409561-B2 | Methods and compositions for treatment of ion imbalances | RELYPSA, INC. (US) | 2013-04-02 | — | — | US | claimed |
| US-20110033505-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | RELYPSA, INC. (US) | 2011-02-10 | — | — | US | claimed |
| EP-2152266-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | Ironwood Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008137318-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| EP-1732524-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | ILYPSA INC (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1732524-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | Ilypsa, Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060024265-A1 | Administering sodium-binding polymer of a core-shell, having an in vivo sodium binding capacity of 4 mmol or more per gram of polymer for removing sodium in gastro-intestinal tract ; treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, fluid overload | VIFOR (INTERNATIONAL) LTD. (CH) | 2006-02-02 | — | — | US | claimed |
| WO-2005094384-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | ILYPSA, INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20050220750-A1 | Methods and compositions for treatment of ion imbalances | SYMYX THERAPEUTICS, INC. (US) | 2005-10-06 | — | — | US | claimed |
| EP-2671584-A2 | Compositions and methods for treating disorders associated with salt or fluid retention | Ironwood Pharmaceuticals, Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8409561-B2 | Methods and compositions for treatment of ion imbalances | RELYPSA, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1732524-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | RELYPSA INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8147873-B2 | Administering sodium binding polymer; hypotensive agents; cardiovascular disorders, liver disorders; crosslinking fluoroacrylic acid | RELYPSA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120040025-A9 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | IRONWOOD PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20080260679-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | RELYPSA, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1732524-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | ILYPSA INC (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1732524-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | Ilypsa, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060024265-A1 | Administering sodium-binding polymer of a core-shell, having an in vivo sodium binding capacity of 4 mmol or more per gram of polymer for removing sodium in gastro-intestinal tract ; treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, fluid overload | VIFOR (INTERNATIONAL) LTD. (CH) | 2006-02-02 | — | — | US | disclosed |
| WO-2005094384-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | ILYPSA, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050220750-A1 | Methods and compositions for treatment of ion imbalances | SYMYX THERAPEUTICS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260679-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | SLC10A1, SLC9A5, SLC9A3 | CA2 35/4885CA1 318/4885LCK 2989/4885 |
| US-20060024265-A1 | Administering sodium-binding polymer of a core-shell, having an in vivo sodium binding capacity of 4 mmol or more per gram of polymer for removing sodium in gastro-intestinal tract ; treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, fluid overload | SLC10A2, SLC10A1, SLC9A3 | CA2 123/4885CA1 588/4885LCK 4671/4885 |
| US-20110033505-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | SLC10A1, SLC9A5, SLC9A3 | CA2 35/4885CA1 318/4885LCK 2989/4885 |
| US-20120040025-A9 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | SLC10A2, SLC10A1, SLC26A3 | CA2 285/4885CA1 640/4885LCK 4423/4885 |
| US-20050220750-A1 | Methods and compositions for treatment of ion imbalances | SLC10A1, SLC9A5, SLC9A3 | CA2 35/4885CA1 318/4885LCK 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.